Capricor Therapeutics (CAPR) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Prothena (PRTA) over the past year, gaining 8.0% versus a loss of 16.6%. Over five years, CAPR leads with a +104.5% price change compared with -86.6% for PRTA. Capricor Therapeutics is the larger company by market cap ($470.9 million vs $435.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | PRTA |
|---|---|---|
| Share price | $8.10 | $8.48 |
| Market cap | $470.93M | $435.34M |
| 1-day change | +4.52% | +5.74% |
| YTD return | -71.93% | -11.20% |
| 1-year return | +8.00% | -16.62% |
| 5-year return | +104.55% | -86.64% |
| EPS (TTM) | $-2.45 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $11.80 |
| 52-week low | $2.96 | $7.73 |
| Distance from 52-week high | -79.94% | -28.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +233.33% | +152.36% |
| Average volume | 6.83M | 478.70K |
| Shares outstanding | 58.14M | 51.34M |
| Employees | 231 | 67 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed PRTA by 24.6 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Healthcare · Biotechnology · 231 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
CAPR vs PRTA FAQ
Which is bigger, Capricor Therapeutics or Prothena?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $470.93M compared with $435.34M for Prothena (PRTA).
Which stock has performed better over the past year, CAPR or PRTA?
CAPR returned +8.00% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.